OBJECTIVES: The aim of this study was to compare the efficiency of two commercial assays, INNO-LiPA Rif.TB and MTBDRplus, for the identification of mutations in the rpoB hot-spot region and to assess the efficiency of these mutations in conferring resistance to rifampicin. METHODS: A collection of 126 rifampicin-resistant Mycobacterium tuberculosis and Mycobacterium africanum isolates and 18 rifampicin-susceptible isolates from different countries were analysed using the two hybridization assays. RESULTS: For 60 strains the hot-spot region of the rpoB gene was sequenced, confirming the results of the hybridization assays and allowing the identification of new mutations. In total, 17 mutations involving 10 codons were observed, two of which are newly described (D516Y and E562G/P564L). Mutations L533P, H526L, D516Y and L511P and the double mutation E562G/P564L conferred a low level of resistance. CONCLUSIONS: The assays INNO-LiPA Rif.TB and MTBDRplus identified rpoB mutations in 98.4% of cases. MTBDRplus provided additional information due to the overlapping hybridization probes and in addition allowed the investigation of katG mutations for isoniazid resistance.
OBJECTIVES: The aim of this study was to compare the efficiency of two commercial assays, INNO-LiPA Rif.TB and MTBDRplus, for the identification of mutations in the rpoB hot-spot region and to assess the efficiency of these mutations in conferring resistance to rifampicin. METHODS: A collection of 126 rifampicin-resistant Mycobacterium tuberculosis and Mycobacterium africanum isolates and 18 rifampicin-susceptible isolates from different countries were analysed using the two hybridization assays. RESULTS: For 60 strains the hot-spot region of the rpoB gene was sequenced, confirming the results of the hybridization assays and allowing the identification of new mutations. In total, 17 mutations involving 10 codons were observed, two of which are newly described (D516Y and E562G/P564L). Mutations L533P, H526L, D516Y and L511P and the double mutation E562G/P564L conferred a low level of resistance. CONCLUSIONS: The assays INNO-LiPA Rif.TB and MTBDRplus identified rpoB mutations in 98.4% of cases. MTBDRplus provided additional information due to the overlapping hybridization probes and in addition allowed the investigation of katG mutations for isoniazid resistance.
Authors: Bertin C Bisimwa; Jean B Nachega; Robin M Warren; Grant Theron; John Z Metcalfe; Maunank Shah; Andreas H Diacon; Nadia A Sam-Agudu; Marcel Yotebieng; André N H Bulabula; Patrick D M C Katoto; Jean-Paul Chirambiza; Rosette Nyota; Freddy M Birembano; Eric M Musafiri; Sifa Byadunia; Esto Bahizire; Michel K Kaswa; Steven Callens; Zacharie M Kashongwe Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Christian Massire; Cristina Agasino Ivy; Robert Lovari; Natalia Kurepina; Haijing Li; Lawrence B Blyn; Steven A Hofstadler; George Khechinashvili; Charles W Stratton; Rangarajan Sampath; Yi-Wei Tang; David J Ecker; Barry N Kreiswirth Journal: J Clin Microbiol Date: 2010-12-29 Impact factor: 5.948
Authors: Michel Kiréopori Gomgnimbou; Iván Hernández-Neuta; Stefan Panaiotov; Elizabeta Bachiyska; Juan Carlos Palomino; Anandi Martin; Patricia del Portillo; Guislaine Refregier; Christophe Sola Journal: J Clin Microbiol Date: 2013-08-21 Impact factor: 5.948
Authors: Graham S Cooke; R Kate Beaton; Richard J Lessells; Laurence John; Simon Ashworth; Onn Min Kon; O Martin Williams; P Supply; P Moodley; Alexander S Pym Journal: Emerg Infect Dis Date: 2011-11 Impact factor: 6.883